| Overview |
| bs-12868R-Cy5.5 |
| BLVRA/Biliverdin Reductase Antibody, Cy5.5 Conjugated |
| FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Rat |
| Mouse, Pig |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human BLVRA/Biliverdin Reductase |
| 161-260/296 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 644 |
| Cytoplasm |
| Biliverdin IX alpha reductase; Biliverdin reductase A; BLVR A; BLVR; BLVRA; BVR A; BVR; BVRA; zinc-metalloprotein; BIEA_HUMAN. |
| In human liver cytosolic fractions, four forms of biliverdin reductase have been identified, including two biliverdin-IX Beta reductases and two biliverdin-IX Alpha reductases, designated isozymes I and II and isozymes III and IV, respectively. Biliverdin reductase A (BLVRA), also designated biliverdin-IX Alpha-reductase, belongs to the GFO/iIDH/MocA family and the biliverdin reductase subfamily. The gene that encodes this cytoplasmic protein maps to chromosome 7p14-cen. BLVRA reduces biliverdin IX ?(the ?methene bridge of the open tetrapyrrole) to bilirubin with the concomitant oxidation of an NADH or NADPH cofactor (bilirubin + NADP+ = biliverdin + NADPH). BLVRA is expressed primarily in liver. |
| Application Dilution |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz